Revenue: As of FY2025 Q3, the actual value is USD 0.EPS: As of FY2025 Q3, the actual value is USD -0.41.EBIT: As of FY2025 Q3, the actual value is USD -3.153 M.<h3>Operational Metrics</h3><ul><li>Net Loss: For the three months ended September 30, 2025, net loss was $3,037,420 compared to $2,999,834 for the same period in 2024, an increase of $37,586 or 1.3%.</li><li>General and Administrative Expenses: For the three months ended September 30, 2025, general and administrative expenses were $1,752,262 compared to $1,423,228 for the same period in 2024, an increase of $329,034 or 23.1%.</li><li>Research and Development Expenses: For the three months ended September 30, 2025, research and development expenses were $1,357,793 compared to $1,581,376 for the same period in 2024, a decrease of $223,583 or 14.1%.</li><li>Loss from Operations: For the three months ended September 30, 2025, loss from operations was $3,110,055 compared to $3,004,604 for the same period in 2024, an increase of $105,451 or 3.5%.</li><li>Other Income, Net: For the three months ended September 30, 2025, other income, net was $72,635 compared to $4,770 for the same period in 2024, an increase of $67,865 or 1,422.7%.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was $9,814,668 compared to $11,480,402 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $7,097,190 compared to $4,541,184 for the same period in 2024.</li><li>Effect of Foreign Currency Translation on Cash: For the nine months ended September 30, 2025, the effect of foreign currency translation on cash was $18,301 compared to - $30,665 for the same period in 2024.</li><li>Decrease in Cash, Cash Equivalents, and Restricted Cash: For the nine months ended September 30, 2025, the decrease in cash, cash equivalents, and restricted cash was $2,699,177 compared to $6,969,883 for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Fair Value of Public Warrants: As of September 30, 2025, the fair value of the Public Warrants was approximately $0.20 per Public Warrant based on the closing price of the warrants on The Nasdaq Capital Market.</li><li>Fair Value of Representative Warrants: As of September 30, 2025, the fair value of the Representative Warrants was approximately $0.20 per Representative Warrant, which was based on the relative fair value to the Public Warrants.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to continue the development of its lead product candidate, PAS-004, with ongoing Phase 1 clinical trials and expects to complete the FIH Phase 1 Dose Escalation Study in 2026. Additionally, the company aims to conduct a Phase 1 trial for pediatric NF1-PN patients and complete registrational clinical trials in both adult and pediatric NF1-PN populations.</li><li>Non-Core Business: The company has two programs in the discovery stage, targeting amyotrophic lateral sclerosis (ALS) for PAS-003 and schizophrenia for PAS-001.</li><li>Priority: The company emphasizes the importance of obtaining additional working capital funding from the sale of equity and/or debt securities to continue its development plans and operations. Management believes that without additional funding, there is substantial doubt about the company’s ability to continue as a going concern through twelve months from the date of these financial statements.</li></ul>

PASITHEA THERAPEUTICS CORP C/WTS 12/08/2026 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 0